临床试验/NCT06422923

NCT06422923招募中1 期

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Temporal Lobe Epilepsy (MTLE)

Neurona Therapeutics27 个研究点分布在 1 个国家目标入组 10 人开始时间: 2024年11月14日最近更新: 2026年1月7日

适应症

干预措施

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 10
试验地点: 27
主要终点: Incidence of Serious Adverse Events at end of month 12

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.

详细描述

This is a multicenter, single arm, open-label study of NRTX-1001 in subjects with drug-resistant bilateral MTLE, with the objective of evaluating safety and preliminary efficacy in reducing seizure frequency. The subjects will undergo a single stereotactic CT or MRI-guided intracerebral administration of human interneurons into both temporal lobe regions of the brain. NRTX-1001 secretes the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is intended to suppress the onset and spread of the seizures. Safety, tolerability, and effects on epilepsy disease symptoms will be assessed at approximately quarterly intervals for 2 years after the administration of NRTX-1001. After the two-year period, subjects will be followed with quarterly phone calls and annual visits in years 3 through 15.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male or female, age 18-75 years.
•Subjects of childbearing potential will use highly effective contraception.
•Proven history of focal seizures of hippocampal origin with bilateral seizure foci confirmed by scalp or intracranial ictal EEG (including confirmation by recordings from responsive neurostimulation [RNS] electrodes when applicable).
•bilateral hippocampal sclerosis on MRI (evidenced by increased FLAIR signal intensity in both hippocampi or by visual assessment showing reduced volume compared to normal) or
•bilateral temporal hypometabolism on 18-Flourodeoxyglucose Positron Emission Tomography (FDG PET) (assessed by visual assessment, comparing temporal regions to frontal/parietal lobe neocortex). In this case, ictal EEG recordings must also include intracranial confirmation.
•a combination of unilateral instances of the evidence described in a. and b. (e.g., one side can be evidenced by criterion a. and the other side by criterion b.) MRI or PET scans used for assessment must have been acquired within 3 years of screening.
•Subject has had at least four clinical focal seizures, including at least two clinical focal seizures with objective manifestations, on average, per month for the 6 months prior to screening.
•Subject has previously had adequate (in opinion of investigator) therapeutic trials of at least two Anti-Seizure Medicines (ASMs).
•Current ASM regimen, and doses of other drugs known to affect seizure frequency (e.g., antidepressants), have been stable for at least three months prior to enrollment.
•Subject can converse and read in English or Spanish. Able to participate in required study procedures and provide signed informed consent.

排除标准

•Epilepsy due to other and/or progressive neurologic disease.
•Evidence of seizure focus outside hippocampus (either by seizure semiology or EEG findings).
•MRI indicating potential malignant lesion (low-grade glioma of any type is excluded) in any location or non-malignant potentially epileptogenic lesion outside the hippocampus. Small (<2 cm) non invasive meningioma, remote from the affected temporal lobe, is not exclusionary.
•Seizures of non-focal origin.
•History of status epilepticus in the year prior to screening, as guided by ILAE criteria (Trinka 2015) in the judgement of the PI. A history of cluster seizures is permitted.
•Psychogenic Non-Epileptic Seizures (PNES) within the past 3 years.
•Severe psychiatric disorders.
•Primary or secondary immunodeficiency.
•Pregnancy, or currently breastfeeding.
•Suicide attempts in past year.
•Significant other medical conditions which would impair safe participation.

研究组 & 干预措施

Treatment Arm

Experimental

This is an open-label study of the bilateral intrahippocampal administration of NRTX-1001 in a single dose cohort of up to 10 subjects with drug-resistant bilateral MTLE.

干预措施: NRTX-1001 (Biological)

结局指标

主要结局

Incidence of Serious Adverse Events at end of month 12

时间窗: 12 months after treatment

次要结局

Change in frequency of clinical seizures(12 months after treatment)

研究者

发起方

Neurona Therapeutics

申办方类型

Industry

责任方

Sponsor

研究点 (27)

Loading locations...

相似试验

已完成

2 期

A Study of ATR-101 for the Treatment of Congenital Adrenal HyperplasiaCongenital Adrenal Hyperplasia

NCT02804178Millendo Therapeutics, Inc.10

已完成

1 期

A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCDPrimary Ciliary Dyskinesia

NCT06600425ReCode Therapeutics7

尚未招募

1 期

Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated HepatitisAlcohol-Associated Hepatitis

NCT06750588Nterica Bio inc12

进行中（未招募）

1 期

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaBeta-Thalassemia

NCT05577312Bioray Laboratories39

已完成

1 期

Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult VolunteersHealthy Volunteers

NCT00517855Protalex, Inc.20